Malik Safiya, Singh Amardeep, Negi Poonam, Kapoor Vijay Kumar
School of Pharmaceutical Sciences, Shoolini University, Solan 173212, India.
School of Pharmaceutical Sciences, Shoolini University, Solan 173212, India.
Drug Discov Today. 2021 Nov;26(11):2716-2725. doi: 10.1016/j.drudis.2021.07.013. Epub 2021 Jul 22.
Thymoquinone (TQ; 2-isopropyl-5-methylbenzo-1, 4-quinone), the main active constituent of Nigella sativa, has been proven to have great therapeutic properties in numerous in vivo and in vitro models. Nevertheless, this molecule is not yet in clinical trials, largely because of its poor bioavailability and hydrophobicity. This review examines the different activities of TQ, as well as various combination therapies, nanotechnologies and clinical trials involving TQ. The TQ nanoparticle formulation shows better bioavailability than free TQ, and it is time for clinical trials of these formulations to realize the potential of TQ as a therapeutic.
百里醌(TQ;2-异丙基-5-甲基苯并-1,4-醌)是黑种草的主要活性成分,已在众多体内和体外模型中被证明具有强大的治疗特性。然而,这种分子尚未进入临床试验,主要原因是其生物利用度低和疏水性强。本文综述了百里醌的不同活性,以及涉及百里醌的各种联合治疗、纳米技术和临床试验。百里醌纳米颗粒制剂显示出比游离百里醌更好的生物利用度,现在是对这些制剂进行临床试验以实现百里醌治疗潜力的时候了。